Hidden Dangers in E-Cigarette Products: A Health Hazard

Aug.08.2024
Hidden Dangers in E-Cigarette Products: A Health Hazard
Duke University researchers reveal tobacco companies substituting unknown, potentially harmful chemicals for nicotine in e-cigarettes to avoid regulations.

According to Mirage News on August 8th, health researchers at Duke University in North Carolina reported that some tobacco companies have started using alternative chemicals with similar characteristics but unknown health impacts to replace nicotine in e-cigarette products in order to circumvent public health regulations.


In a research letter published in the Journal of the American Medical Association on August 7th, researchers from Duke University and Yale University also found that the quantities of these chemicals (known as nicotine analogs) were not accurately disclosed on the packaging.


The study's co-author, Senior Research Scientist Sairam V. Jabba, D.V.M., Ph.D., of Duke University School of Medicine, stated that...


E-cigarette products containing nicotine are restricted by federal law, prohibiting sales to individuals under the age of 21.


Currently, nicotine analogs are not restricted by FDA regulations, and their health effects have not been studied. Our analysis of some e-cigarette products containing analogs sold in the United States found significant and concerning discrepancies between the claimed ingredients and the actual ingredients. Furthermore, manufacturers may be trying to circumvent FDA tobacco regulation.


The study emphasizes that a chemical compound called 6-methyl nicotine is shown in rodent experiments to be more effective and more toxic than nicotine in targeting brain nicotine receptors. Another chemical compound called nicotinamide is advertised as targeting the same brain receptors, although evidence suggests it does not bind to these receptors.


These nicotine analogs are added to flavored e-cigarettes, previous studies have shown that these e-cigarettes are more popular among young people and first-time e-cigarette users.


Jabba and colleagues, including co-senior author Sven Eric Jordt, Ph.D., analyzed a e-cigarette product called Spree Bar, which has at least nine flavors and is labeled as containing 5% 6-methylnicotine. The research findings showed that the actual chemical content was about 88% lower than what was indicated on the label. This e-cigarette also contains an artificial sweetener that is 13,000 times sweeter than sucrose, as well as an artificial cooling agent that mimics the effect of mint.


The second brand of e-cigarette (sold under the names Nixotine, Nixodine, Nixamide, and Nic-Safe) contains a nicotine analogue called niacin, with levels lower than indicated on the label, and combined with an undisclosed amount of 6-methyl nicotine. This brand does not contain any sweeteners or cooling agents.


These products appear to be designed to circumvent laws and regulations aimed at protecting people, especially children, from the harmful effects of smoking and tobacco use. We do not know what effects these chemicals may have when heated and inhaled. These questions should be answered before allowing the products to be marketed.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23